EUVIMEDEUVIMED entdecken
Crossref

Outcome of second‐line therapy in adult B‐cell acute lymphoblastic leukemia

Hagop Kantarjian iD, Wei Qiao, Nitin Jain, Wei-Ying Jen, Eitan Kugler iD, Nicholas J Short iD, Rebecca Garris, Sherry Pierce, Partow Kebriaei, Sa A Wang, Fadi Haddad iD, Farhad Ravandi und 2 weitere

Cancer · 15.04.2026 · 132 (8)

DOI: 10.1002/cncr.70401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 09.04.2026. Verfasst von Hagop Kantarjian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Study Aims Historically, adults with B‐cell acute lymphoblastic leukemia (ALL) treated with standard intensive chemotherapy in first salvage had a complete response rate of 40% and a 3‐year survival rate

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salvage TherapyAntineoplastic Combined Chemotherapy ProtocolsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansFemaleAdultMiddle AgedMaleAgedRemission InductionTreatment OutcomeYoung AdultAdolescentAntibodies, BispecificSurvival RateRetrospective Studies

Stichwörter der Autor:innen

ALL salvage therapyCARTblinatumomabinotuzumab

Substanzen

blinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Hagop Kantarjian, Eitan Kugler, Nicholas J Short, Fadi Haddad, Elias Jabbour

Förderung

  • NCI NIH HHS

Zitieren

APA

Kantarjian, H., Qiao, W., Jain, N., Jen, W. Y., Kugler, E., Short, N. J., Garris, R., Pierce, S., Kebriaei, P., Wang, S. A., Haddad, F., Ravandi, F., Huang, X., & Jabbour, E. (2026). Outcome of second‐line therapy in adult B‐cell acute lymphoblastic leukemia. Cancer, 132(8). https://doi.org/10.1002/cncr.70401

Vancouver

Kantarjian H, Qiao W, Jain N, Jen WY, Kugler E, Short NJ, et al. Outcome of second‐line therapy in adult B‐cell acute lymphoblastic leukemia. Cancer. 2026;132(8). doi:10.1002/cncr.70401

BibTeX
@article{Kantarjian2026,
  author = {Kantarjian, Hagop and Qiao, Wei and Jain, Nitin and Jen, Wei-Ying and Kugler, Eitan and Short, Nicholas J and Garris, Rebecca and Pierce, Sherry and Kebriaei, Partow and Wang, Sa A and Haddad, Fadi and Ravandi, Farhad and Huang, Xuelin and Jabbour, Elias},
  title = {Outcome of second‐line therapy in adult B‐cell acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {8},
  doi = {10.1002/cncr.70401}
}
Kostenlos starten →